Quarterly ResultAug 12, 2026, 04:38 PM
VIVOS INC Reports H1 2026 Net Loss of $2.01M; Going Concern Doubts
AI Summary
VIVOS INC reported a net loss of $2.01 million for the six months ended June 30, 2026, an increase from $1.48 million in the prior year, primarily due to a loss on issuance of shares and warrant exchange. Despite a revenue increase to $72,468 for the period, the company's recurring losses and insufficient cash raise significant doubt about its ability to continue as a going concern. VIVOS INC requires $3 million annually for operations and an additional $9 million over 36 months for strategic initiatives, including FDA approval for RadioGel® and expansion of IsoPet® animal therapy.
Key Highlights
- Net loss for the six months ended June 30, 2026, was $2.01 million, up from $1.48 million in H1 2025.
- Revenue for the six months ended June 30, 2026, increased to $72,468 from $41,748 in H1 2025.
- Company's independent auditor expressed substantial doubt about its ability to continue as a going concern.
- Requires $3 million annually to maintain current operating activities.
- Needs approximately $9 million in additional capital over 36 months for FDA approval and clinical trials.
- Cash on hand as of June 30, 2026, was $2.34 million.
- Total assets increased to $2.88 million from $1.87 million at December 31, 2025.
- Total liabilities decreased to $123,955 from $206,743 at December 31, 2025.
Price Impact